Cancer drug developer ApeX Therapeutics has appointed Steve Carchedi president and CEO of the Indianapolis, IN-based company. He succeeds David Broecker, who will continue to serve on the company’s board of directors.
Carchedi comes to ApeX from Cranbury, NJ-based Cornerstone Pharmaceuticals. His experience also includes various roles at Covidien, Bristol-Myers Squibb (NYSE: BMY), Eli Lilly (NYSE: LLY), and Johnson and Johnson (NYSE: JNJ). ApeX says its lead drug candidate, APX3330, targets a protein found in many cancers.